Literature DB >> 14566735

Early failure mechanisms of constrained tripolar acetabular sockets used in revision total hip arthroplasty.

Christopher C Cooke1, William Hozack, Carlos Lavernia, Peter Sharkey, Shani Shastri, Richard H Rothman.   

Abstract

Fifty-eight patients received an Osteonics constrained acetabular implant for recurrent instability (46), girdlestone reimplant (8), correction of leg lengthening (3), and periprosthetic fracture (1). The constrained liner was inserted into a cementless shell (49), cemented into a pre-existing cementless shell (6), cemented into a cage (2), and cemented directly into the acetabular bone (1). Eight patients (13.8%) required reoperation for failure of the constrained implant. Type I failure (bone-prosthesis interface) occurred in 3 cases. Two cementless shells became loose, and in 1 patient, the constrained liner was cemented into an acetabular cage, which then failed by pivoting laterally about the superior fixation screws. Type II failure (liner locking mechanism) occurred in 2 cases. Type III failure (femoral head locking mechanism) occurred in 3 patients. Seven of the 8 failures occurred in patients with recurrent instability. Constrained liners are an effective method for treatment during revision total hip arthroplasty but should be used in select cases only.

Entities:  

Mesh:

Year:  2003        PMID: 14566735     DOI: 10.1016/s0883-5403(03)00325-5

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  16 in total

1.  Constrained cups appear incapable of meeting the demands of revision THA.

Authors:  Philip C Noble; Salim K Durrani; Molly M Usrey; Kenneth B Mathis; Nikolaos V Bardakos
Journal:  Clin Orthop Relat Res       Date:  2012-07       Impact factor: 4.176

2.  The use of a cemented dual mobility socket to treat recurrent dislocation.

Authors:  Moussa Hamadouche; David J Biau; Denis Huten; Thierry Musset; François Gaucher
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

3.  The use of a dual-articulation acetabular cup system to prevent dislocation after primary total hip arthroplasty: analysis of 384 cases at a mean follow-up of 15 years.

Authors:  Remi Philippot; Jean Philippe Camilleri; Bertrand Boyer; Philippe Adam; Frederic Farizon
Journal:  Int Orthop       Date:  2008-06-03       Impact factor: 3.075

4.  Use of a dual mobility socket to manage total hip arthroplasty instability.

Authors:  Olivier Guyen; Vincent Pibarot; Gualter Vaz; Christophe Chevillotte; Jacques Béjui-Hugues
Journal:  Clin Orthop Relat Res       Date:  2008-09-09       Impact factor: 4.176

5.  Are abductor muscle quality and previous revision surgery predictors of constrained liner failure in hip arthroplasty?

Authors:  Michael G Zywiel; Loi'y H Mustafa; Peter M Bonutti; Michael A Mont
Journal:  Int Orthop       Date:  2010-02-20       Impact factor: 3.075

6.  Instability after total hip arthroplasty.

Authors:  Brian C Werner; Thomas E Brown
Journal:  World J Orthop       Date:  2012-08-18

7.  Constrained liner in neurologic or cognitively impaired patients undergoing primary THA.

Authors:  Philippe Hernigou; Paolo Filippini; Charles-Henri Flouzat-Lachaniette; Sobrinho Uirassu Batista; Alexandre Poignard
Journal:  Clin Orthop Relat Res       Date:  2010-12       Impact factor: 4.176

Review 8.  Total hip arthroplasty instability in Italy.

Authors:  Francesco Falez; Matteo Papalia; Fabio Favetti; Gabriele Panegrossi; Filippo Casella; Gianluca Mazzotta
Journal:  Int Orthop       Date:  2016-12-20       Impact factor: 3.075

9.  Acetabular liner with focal constraint to prevent dislocation after THA.

Authors:  Jacob T Munro; Mihai H Vioreanu; Bassam A Masri; Clive P Duncan
Journal:  Clin Orthop Relat Res       Date:  2013-12       Impact factor: 4.176

10.  Dual mobility cemented cups have low dislocation rates in THA revisions.

Authors:  Frantz L Langlais; Mickaël Ropars; François Gaucher; Thierry Musset; Olivier Chaix
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.